<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335526</url>
  </required_header>
  <id_info>
    <org_study_id>MMP2</org_study_id>
    <nct_id>NCT04335526</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles</brief_title>
  <official_title>A Clinical Study for Assessing the Effect of Change of Bile Acid Pool on the Pharmacodynamics and Safety of Metformin and Intestinal Microbiome Profiles in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is intended to evaluate the effect of change of bile acid pool with
      cholestyramine on the pharmacodynamics and safety of metformin and intestinal microbiome
      profiles in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the maximum blood glucose concentration (Gmax)</measure>
    <time_frame>Day 1/2/8/9 (pre-dose (75 g glucose), 0.25, 0.5, 0.75, 1, 1.5. 2 hours)</time_frame>
    <description>Compare the maximum blood glucose concentration (Gmax) between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the maximum blood glucose concentration (Gmax)</measure>
    <time_frame>Day 1/2/8/9 (pre-dose (75 g glucose), 0.25, 0.5, 0.75, 1, 1.5. 2 hours)</time_frame>
    <description>Compare the area under the blood glucose concentration versus time curve (AUC) between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the gut microbiome species change</measure>
    <time_frame>Day 1/2/8/9</time_frame>
    <description>Compare how the gut microbiome species change between meformin alone and meformin with cholestyramine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Metformin alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin with cholestyramine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine Resin</intervention_name>
    <description>Change bile acid pool by cholestyramine treatment</description>
    <arm_group_label>Metformin with cholestyramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19 to 50, healthy male subjects(at screening)

          -  Body weight between 50.0 kg - 100.0 kg, BMI between 18.0 - 28.0 kg/m2

          -  Subject who totally understand the progress of this clinical trials, make decision by
             his free will, and signed a consent form to follow the progress

        Exclusion Criteria:

          -  Subject who has a past or present history of any diseases following below.(liver,
             kidney, neurology, immunology, pulmonary, endocrine, hematology, oncology, cardiology,
             mental disorder)

          -  Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic
             pancreatitis) or surgery (appendectomy, hernioplasty are excluded)

          -  Serum AST(SGOT), ALT(SGPT)&gt;2 times upper limit of normal range MDRD eGFR
             &lt;80mL/min/1.73m2

          -  Subject who had drug (Aspirin, antibiotics) hypersensitivity reaction

          -  Subject who already participated in other trials in 3 months

          -  Subject who had whole blood donation in 2 months, or component blood donation in 1
             month or transfusion in 1 month currently
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chung Jae Yong, MD, PhD</last_name>
    <phone>+82-31-787-3968</phone>
    <email>mekka@snu.ac.kr</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

